Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are considered a breakthrough in cancer therapy. Currently approved for breast cancer treatment, CDK4/6 inhibitors are extensively tested in other cancer subtypes. Frequently observed side effects include hematological abnormalities such as reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurer, Barbara, Brandstoetter, Tania, Kollmann, Sebastian, Sexl, Veronika, Prchal-Murphy, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485667/
https://www.ncbi.nlm.nih.gov/pubmed/32855282
http://dx.doi.org/10.3324/haematol.2020.256313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485667/
https://www.ncbi.nlm.nih.gov/pubmed/32855282
http://dx.doi.org/10.3324/haematol.2020.256313

Ejemplares similares